GU Cancers 2022 | BLASST-1: nivolumab + gemcitabine-cisplatin before radical cystectomy in muscle-invasive BC

Shilpa Gupta, MD, University of Minnesota, Minneapolis, MN, discusses the Phase II BLASST-1 trial (NCT03294304), involving 41 patients with muscle-invasive bladder cancer treated with neoadjuvant nivolumab and gemcitabine-cisplatin, who subsequently underwent radical cystectomy. Results presented at ASCO GU 2022 consisted of a clinical follow-up (median of 15.8 months) and biomarker analysis (involving DNA sequencing, RNA-based analysis and PD-L1 testing). The 12-month recurrence-free survival was 85.4%, with a progression-free survival of 83%. There was no correlation of responses with PD-L1 expression. Dr Gupta also discusses the differences in response between basal-type and luminal-type disease. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.